A Combination of Native LC-MS Approaches for the Comprehensive Characterization of the Antibody-Drug Conjugate Trastuzumab Deruxtecan.
Fiche publication
Date publication
octobre 2022
Journal
Frontiers in bioscience (Landmark edition)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CIANFERANI Sarah, Pr PIVOT Xavier, Dr DETAPPE Alexandre, Dr COLIAT Pierre
Tous les auteurs :
Deslignière E, Diemer H, Erb S, Coliat P, Pivot X, Detappe A, Hernandez-Alba O, Cianférani S
Lien Pubmed
Résumé
Native mass spectrometry (nMS) approaches appear attractive to complement bottom-up strategies traditionally used in biopharmaceutical industries thanks to their quite straightforward and rapid workflows, especially through online hyphenation of non-denaturing liquid chromatography (LC) to nMS. The present work provides an overview of the state-of-the-art chromatographic tools available for the detailed characterization of monoclonal antibody (mAb) formats, exemplified on the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd).
Mots clés
antibody-drug conjugate (ADC), biotherapeutics, cation exchange chromatography (CEX), higher order structures, hydrophobic interaction chromatography (HIC), liquid chromatography (LC), native mass spectrometry (MS), size exclusion chromatography (SEC)
Référence
Front Biosci (Landmark Ed). 2022 10 26;27(10):290